Advertisement

Multiple esophageal ulcers due to tofacitinib 10 mg twice daily for ulcerative colitis

  • Keiichi TominagaEmail author
  • Mimari Kanazawa
  • Kazuhiro Takenaka
  • Takanao Tanaka
  • Takeshi Sugaya
  • Koh Fukushi
  • Yuka Takagi
  • Kazunori Nagashima
  • Keiichiro Abe
  • Naoya Izawa
  • Kohei Tsuchida
  • Makoto Iijima
  • Kenichi Goda
  • Hidetsugu Yamagishi
  • Atsushi Irisawa
Case Report
  • 8 Downloads

Abstract

A 26-year-old man was admitted to our institution for ulcerative colitis treatment. He used mesalamine, steroid, immunomodulators, and anti-TNFα anti-body, but it was difficult to maintain remission. We started induction therapy with tofacitinib (TOF) 10 mg twice daily. He maintained clinical remission but had chest pain 44 days after the start of TOF. Esophagogastroduodenoscopy showed multiple ulcers from middle to lower esophagus. Although rare, TOF induced esophageal ulcers were considered based on his clinical course and endoscopic findings.

Keywords

Janus kinase inhibitor Tofacitinib Ulcerative colitis Esophageal ulcers 

Notes

Funding

None.

Compliance with ethical standards

Conflict of interest

Keiichi Tominaga, Mimari Kanazawa, Kazuhiro Takenaka, Takanao Tanaka, Takeshi Sugaya, Koh Fukushi, YukaTakagi, Kazunori Nagashima, Keiichiro Abe, Naoya Izawa, Kohei Tsuchida, Makoto Iijima, Kenichi Goda, Hidetsugu Yamagishi, and Atsushi Irisawa declear that they have no conflict of interest.

Human/animal rights

All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all patients for being included in the study.

References

  1. 1.
    Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25–36.CrossRefGoogle Scholar
  2. 2.
    Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36.CrossRefGoogle Scholar
  3. 3.
    Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;24:2258–65.CrossRefGoogle Scholar
  4. 4.
    Motoya S, Watanabe M, Kim HJ, et al. Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies. Intest Res. 2018;16:233–45.CrossRefGoogle Scholar
  5. 5.
    Jung KH, Choi J, Gong EJ, et al. Can endoscopists differentiate cytomegalovirus esophagitis from herpes simplex virus esophagitis based on gross endoscopic findings? Medicine (Baltimore). 2019;98:e15845.CrossRefGoogle Scholar
  6. 6.
    Werneck-Silva AL, Prado IB. Role of upper endoscopy in diagnosing opportunistic infections in human immunodeficiency virus-infected patients. World J Gastroenterol. 2009;15:1050–6.CrossRefGoogle Scholar
  7. 7.
    Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2173–82.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  • Keiichi Tominaga
    • 1
    Email author
  • Mimari Kanazawa
    • 1
  • Kazuhiro Takenaka
    • 1
  • Takanao Tanaka
    • 1
  • Takeshi Sugaya
    • 1
  • Koh Fukushi
    • 1
  • Yuka Takagi
    • 1
  • Kazunori Nagashima
    • 1
  • Keiichiro Abe
    • 1
  • Naoya Izawa
    • 1
  • Kohei Tsuchida
    • 1
  • Makoto Iijima
    • 1
  • Kenichi Goda
    • 1
  • Hidetsugu Yamagishi
    • 2
  • Atsushi Irisawa
    • 1
  1. 1.Department of GastroenterologyDokkyo Medical UniversityShimotsugaJapan
  2. 2.Department of Diagnostics PathologyDokkyo Medical UniversityTochigiJapan

Personalised recommendations